Exhaled NO in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment

In adult patients with cystic fibrosis (CF) fraction of exhaled nitric oxide (FeNO) has been reported to be normal or abnormally low [1]. FeNO has also been reported to correlate with spirometry [2–4], and to increase following treatment with ivacaftor [5, 6], suggesting that FeNO could be used as a non-invasive, fast and easily available marker of CFTR-function. The aim of this study was to examine whether in adult CF patients, FeNO was associated with patient characteristics and lung function, and whether FeNO was affected by acute exacerbation. We also aimed to examine FeNO evolution over a longer period after starting CFTR-modifying treatment (ivacaftor and ivacaftor/lumacaftor).Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Vincken has nothing to disclose.Conflict of interest: Dr. Verbanck has nothing to disclose.Conflict of interest: Dr. De Wachter has nothing to disclose.Conflict of interest: Dr. Vanderhelst has nothing to disclose.